Tuberculosis Vaccine Development and Immune Response

Tuberculosis remains a leading cause of infectious mortality worldwide, driven by the airborne transmission of Mycobacterium tuberculosis and the emergence of drug-resistant strains. The only licensed vaccine, Bacille Calmette–Guérin (BCG), provides variable protection against pulmonary disease in adults and wanes over time. Research efforts now focus on understanding the immune mechanisms required for durable protection, including innate activation of macrophages, antigen presentation by dendritic cells and the induction of CD4+ and CD8+ T-cell subsets that exhibit interferon-γ and tumour necrosis factor-α production. Vaccine platforms under investigation range from subunit formulations with defined antigens and novel adjuvants to live viral vectors and nucleic acid approaches. Key challenges include stabilising vaccine formulations for use in low-resource settings, targeting antigens expressed during acute, chronic and dormant phases of infection, and eliciting mucosal immunity at the site of infection. Preclinical models and early clinical trials emphasise the need for polyfunctional T cells and robust humoral responses to support macrophage activation and mycobacterial clearance. Collaborative global trials seek to bridge preclinical promise to real-world efficacy, with an emphasis on scalable production and distribution to populations most at risk.

Research from Nature Portfolio

Recent studies have demonstrated that a thermostable lyophilised formulation of a fusion subunit vaccine combined with a Toll-like receptor 4 agonist adjuvant can be administered in a single vial without refrigeration, significantly enhancing its practicality for field use. In a Phase 1 trial involving healthy adult volunteers, this vaccine elicited strong antigen-specific IgG responses and Th1-type cellular immunity, as measured by interferon-γ and tumour necrosis factor-α production from peripheral blood mononuclear cells. The thermostable formulation induced higher antibody titres and increased antibody-secreting cell frequencies compared with the conventional two-vial presentation, while maintaining an acceptable safety profile. These findings underscore the feasibility of advancing subunit vaccine candidates that combine immunogenicity with thermal resilience for global deployment.

Tuberculosis Vaccine Development and Immune Response publication trend

The graph below shows the total number of articles in tuberculosis vaccine development and immune response across all publications each year (not limited to Nature Index journals).

Technical terms

Adjuvant: Substance that amplifies and shapes the immune response to a vaccine antigen.

Subunit vaccine: Formulation containing specific purified antigen fragments rather than whole organisms.

Th1-type response: T helper cell response characterised by interferon-γ and tumour necrosis factor-α production, crucial for macrophage activation.

Mucosal immunity: Localised immune protection at epithelial surfaces, such as the respiratory tract, providing first-line defence against inhaled pathogens.

Viral-vectored vaccine: Vaccine employing a non-replicating virus to deliver genes encoding target antigens, stimulating cellular immunity.

Polyfunctional T cell: T cell capable of producing multiple cytokines simultaneously, often associated with effective immunity.

References

1. Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults. Nature Communications (2023).
2. Tuberculosis vaccines and therapeutic drug: challenges and future directions. Molecular Biomedicine (2025).
3. Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice. npj Vaccines (2023).